Robert I. Haddad, Renata Ferrarotto, Ye Guo, Kevin Joseph Harrington, Lisa F. L. Licitra, Nabil F. Saba, Makoto Tahara, Pablo Nenclares, Irene Braña, John Xie, Pei-Ling Chu, Mariah Ennis, Jessica Dobbs, Brooke Diorio, Priya Kim, Sujay Shah, Barbara Burtness. "OrigAMI-5: A randomized, phase 3 study of amivantamab plus pembrolizumab and carboplatin vs standard of care pembrolizumab plus platinum and 5-fluorouracil as first-line treatment in recurrent/metastatic head and neck cancer.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.tps6127